Onesource Specialty Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 22, 2025
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma Limited (formerly Stelis Biopharma) held its 18th AGM on September 22, 2025 via video conferencing, the company's first AGM since listing on the stock exchanges. 49 members holding approximately 1.19 crore equity shares attended the meeting, which ran from 5:00 PM to 6:23 PM IST. Six ordinary resolutions were transacted, including adoption of audited FY25 financial statements, re-appointment of Arun Kumar (retiring by rotation), remuneration to the Cost Auditor for FY26, appointment of M/s. DV & Associates as Secretarial Auditor for five years, and approval of material related party transactions with Strides Pharma Science Limited and Strides Pharma Inc, USA. The auditor's report contained no qualifications or adverse comments, and e-voting results were to be declared within two working days (by September 24, 2025). Bharat Shah chaired the meeting as Arun Kumar, along with two other directors, sought leave of absence.
This is a routine AGM proceedings filing with no major negative signals — the clean audit report and passage of all six ordinary resolutions are constructive for shareholders. The material RPTs with Strides Pharma group entities are significant for retail investors to monitor, and since voting outcomes are pending, investors should watch for the September 24 results to confirm shareholder approval.